

Interim commissioning position:

To standardise process and respond to the needs within the local ICS for funding of HCDs for clinical indications which would generally be funded by NHS England for Children and young people (CYP), and then transfer to CCG routine commissioning for adults, it is proposed that the following interim commissioning statement is adopted:

Bedfordshire, Luton & Milton Keynes CCG/ICB will commission high cost drugs for paediatric patients in the following circumstances:

* The patient is aged 16 or 17 years and is under the care of the relevant adult service.
* The request is for a medicine approved by NICE for adult conditions which would be commissioned by NHS England in children at specialised paediatric centres. Namely:
	+ The patient meets the NICE (adult) criteria and there is evidence to suggest that the drug is safe and clinically appropriate to use in children as per the NHS England Medicines for Children Policy (see <https://www.england.nhs.uk/publication/commissioning-medicines-for-children-specialised-services/>)
	+ There is a NHS England Blueteq form available for the treatment/condition.
* A high cost drug funding form has been submitted to the CCG/ICB (preferably via Blueteq).

These conditions will not apply when:

* The medicine is routinely commissioned by the CCG/ICB for the medication and condition being requested i.e. there is NICE technology appraisal guidance or a local policy available which applies to children and young people <18 years of age and the CCG/ICB is the responsible commissioner.
* The medicine is not routinely commissioned by the CCG/ICB for the medication and clinical condition being requested.
* The request is received from a Trust in another area and the host commissioner has a different policy in place (informal or formal).

If the above conditions are not met, submission of an individual funding request (IFR) will be required. See <https://www.blmkccg.nhs.uk/your-health/individual-funding/policy-and-process/> for more information.